Category: Cardiogenic Shock
Sites participating in the National Cardiogenic Shock Initiative (CSI) have adopted the National CSI algorithm as the foundation for their treatment of AMI (STEMI & NSTEMI) patients who present in cardiogenic shock. Learn more at www.henryford.com/national-csi IMP-104-17 v2
Successful Implementation of Cardiogenic Shock Algorithm Dr. Salvatore Mannino discusses the cardiogenic shock algorithm used in his successful spoke and hub network. Dr. Mannino is director of the short-term mechanical circulatory support program at WellStar Health System, the largest healthcare system in Georgia. Starting in 2016, each hospital in the WellStar spoke and hub network … Continue reading “WellStar Hub and Spoke Cardiogenic Shock Treatment Network”
A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardiogenic Shock Initiative support the recommendation that placing Impella 2.5 or Impella CP pre-PCI improves outcomes.
Use this checklist to guide treatment decisions and determine if the Impella RP is right for your patients. IMP-796
Adoption of best practices improves survival for patients with Acute Myocardial Infarction and Cardiogenic Shock (AMICS) supported with Impella.
The Impella 5.0 is approved for use in cardiogenic shock, and is proven to unload the left ventricle and support the systemic circulation. IMP-127 .v3
The Impella RP is the only FDA approved support device for the treatment of right heart failure.
The use of standardized protocols has been associated with improvement in outcomes for people in cardiogenic shock. Such protocols enable clinicians to quickly assess a situation and rapidly decide on next steps. These protocols present Abiomed’s cardiogenic shock guidelines and include best practices to identify, stabilize, revascularize, and reassess high-risk cardiogenic shock patients. Inserting mechanical … Continue reading “Abiomed’s Cardiogenic Shock Guidelines”
Impella 2.5®, Impella CP®, Impella 5.0®, and Impella LD® heart pumps are now FDA indicated to provide treatment of ongoing cardiogenic shock. In this setting, the Impella® heart pumps have the ability to stabilize the patient’s hemodynamics, unload the left ventricle, perfuse the end organs, and allow for recovery of the native heart.